NCT03725891 is a NA clinical trial of Aspirin 162 mg in Preeclampsia, sponsored by Aswan University Hospital.

Who is sponsoring NCT03725891?

NCT03725891 is sponsored by Aswan University Hospital.

What drugs are being tested in NCT03725891?

Interventions in NCT03725891: Aspirin 162 mg, Aspirin 81 mg, placebo.

What condition does NCT03725891 study?

NCT03725891 studies Preeclampsia.

Is NCT03725891 still recruiting?

NCT03725891 is currently status unknown. Last updated 10 January 2019.

Last reviewed 2019-01-10 · How we verify

NCT03725891

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Aspirin for Prevention of Preeclampsia in Healthy, Nulliparous Obese and Overweight Pregnant Women

Status unknown NA Last updated 10 January 2019

What this trial tests

NA trial testing Aspirin 162 mg in Preeclampsia in 600 participants. Status unknown.

Timeline

1 December 2018

Primary endpoint
30 November 2021

1 January 2022

Quick facts

Lead sponsor	Aswan University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	600
Start date	1 December 2018
Primary completion	30 November 2021
Estimated completion	1 January 2022
Sites	1 location across Egypt

Drugs / interventions tested

Aspirin 162 mg — full drug profile →
Aspirin 81 mg — full drug profile →
placebo

Conditions studied

Preeclampsia — all drugs for Preeclampsia →

Sponsor

Aswan University Hospital

Who can join

Adults 18 to 45, female only, with Preeclampsia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Preeclampsia is a pregnancy-specific syndrome that affects 3 - 5% of pregnancies. It is one of the main causes of maternal, fetal and neonatal morbidity and mortality, resulting in approximately 40,000 maternal deaths worldwide each year. Fortunately, preeclampsia-related deaths have been reduced remarkably in recent decades thanks to improvements in antenatal care and therapeutic interventions, and prophylactic use of low-dose aspirin in women who are at a higher risk of developing preeclampsia. Effective prevention is rarely available for obstetric complications. Aspirin is one of them. Several meta-analyses456 suggested that aspirin prescription reduced the risk of preeclampsia and fetal growth restriction by 40-50% in an aspirin-dose-response pattern.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pregnancy Interventions to Improve Birth Outcomes: What Are the Effects on Maternal Outcomes? A Scoping Review.
Zavala E, Rhodes M, Christian P. · · 2022 · cited 5× · PMID 36405527 · DOI 10.3389/ijph.2022.1604620

Verify or expand the search:

Other trials of Aspirin 162 mg

Trials testing the same drug.

NCT06468202 — Effectiveness of Two Aspirin Doses for Prevention of Hypertensive Disorders of Pregnancy: ASPIRIN TRIAL · Phase 4 · recruiting
NCT05221164 — 162 mg of Aspirin for Prevention of Preeclampsia · Phase 4 · unknown
NCT03961360 — Effectiveness of Higher Aspirin Dosing for Prevention of Preeclampsia in High Risk Obese Gravida · Phase 2, PHASE3 · completed

Other recruiting trials for Preeclampsia

Currently open trials in the same condition.

NCT06953115 — Vagal Stimulation Therapy and Preeclampsia · NA · recruiting
NCT06333652 — Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders · Phase 2 · recruiting
NCT07282171 — A Study to Investigate the Safety, Pharmacodynamic and Pharmacokinetic Characteristics of CBP-4888 in Hospitalized Parti · Phase 1 · recruiting
NCT07345845 — MR and Inflammation After Preeclampsia · EARLY_PHASE1 · active not recruiting
NCT07041281 — Spironolactone to Improve Pregnancy-Associated Hypertension Trajectories · Phase 2 · recruiting

Other Aswan University Hospital trials

Trials by the same sponsor.

NCT06491394 — Lactoferrin Effect on Kidney and Heart of Rhabdomyolysis Rats · Phase 4 · completed
NCT06211088 — Famotidine Versus Placebo in Emergency Pediatric Surgery As a Risk to Postoperative Nausea and Vomiting · NA · completed
NCT06583590 — Evaluation of Efficacy of Botulinum Toxin A Plus Oral Tadalafil 5 mg in Diabetic Men With Erectile Dysfunction · Phase 2, PHASE3 · recruiting
NCT06537323 — Femoral Nerve Block, Periarticular Nerve Group (PENG) Block, and Preoperative IV Fentanyl · NA · recruiting
NCT06535256 — Compare Intraperitoneal Instillation of Bupivacaine+dexmedetomidine Versus Bupivacaine+dexamethasone on Postoperative Pa · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03725891 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aswan University Hospital
Last refreshed: 10 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03725891.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing